Basic Xeloda Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In United Kingdom: Glucophage; generics labelled as Metformin supplied by manufacturers such as Teva, Sandoz, Accord Healthcare and Aurobindo
• ATC Code: A10BA02
• Forms & Dosages: Immediate‑release tablets (500 mg, 850 mg, 1000 mg) and extended‑release tablets (500 mg, 750 mg, 1000 mg); oral solution 500 mg/5 mL for paediatric use
• Manufacturers In United Kingdom: Multiple global and local suppliers supply metformin into UK formularies including Teva, Sandoz and Accord Healthcare
• Registration Status In United Kingdom: Approved and listed by MHRA; widely used as first‑line oral antidiabetic
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Which trials have changed how clinicians use xeloda and what do they mean for patients?

Major 2022–2025 studies prioritised capecitabine (Xeloda) in three main areas: adjuvant escalation for HER2‑negative breast cancer with residual disease, oral substitution for infusional 5‑FU in colorectal regimens, and combinations with immune checkpoint inhibitors in metastatic settings.

Selected trials showed improved disease‑free survival when capecitabine was added in high‑risk post‑neoadjuvant breast cancer cohorts, supporting targeted adjuvant escalation in that group.

For colorectal cancer, phase II/III data demonstrated non‑inferiority to infusional 5‑FU for many regimens, with similar overall survival but differing toxicity patterns and convenience benefits from oral dosing.

Safety observations across studies highlighted hand‑foot syndrome as the most frequent dose‑limiting toxicity and the cause for most dose reductions.

About a quarter to two‑fifths of patients required dose reductions in trial cohorts, typically for HFS or diarrhoea.

Rare cardiotoxic events were reported, prompting recommendations for baseline cardiovascular assessment in patients with cardiac history before starting capecitabine.

Early real‑world UK registries (2024–2025) reported fewer hospital admissions when oral capecitabine replaced intravenous 5‑FU, improving patient convenience while increasing the need for community monitoring.

NHS pathway adaptations since these trials have leaned towards oral‑first options for suitable patients where safety and adherence can be assured.

Clinical Mechanism Of Action

How does Xeloda work in plain terms?

Capecitabine is an oral prodrug that the body converts into fluorouracil (5‑FU), a chemotherapy agent that interferes with tumour cell DNA and RNA synthesis.

This disruption slows or stops cancer growth and leads to cell death in rapidly dividing tumour cells.

What happens biochemically?

After oral absorption, capecitabine is activated through three enzymatic steps to become 5‑FU at sites with higher thymidine phosphorylase activity, which many tumours express.

The first step is hepatic carboxylesterase converting capecitabine to 5′‑deoxy‑5‑fluorocytidine (5′‑DFCR).

The second step uses cytidine deaminase to make 5′‑deoxy‑5‑fluorouridine (5′‑DFUR).

The final conversion is by thymidine phosphorylase, often enriched in tumours, producing active 5‑FU and increasing tumour selectivity.

Pharmacodynamics: 5‑FU inhibits thymidylate synthase causing thymidine depletion, DNA damage and apoptosis, and it can also be misincorporated into RNA, disrupting RNA processing.

Pharmacokinetics: oral dosing provides predictable systemic exposure but notable interpatient variability related to renal function and DPD activity.

DPD deficiency markedly increases the risk of severe toxicity and is screened for in UK practice before starting capecitabine.

Enzymatic Activation Steps

Step 1: Carboxylesterase converts capecitabine to 5′‑DFCR in the liver.

Step 2: Cytidine deaminase converts 5′‑DFCR to 5′‑DFUR in liver and tumour tissue.

Step 3: Thymidine phosphorylase, higher in many tumours, converts 5′‑DFUR to active 5‑FU locally.

Scope Of Approved And Off‑Label Use

Which cancers is Xeloda licensed for in the UK and where is it used beyond the licence?

United Kingdom approvals include capecitabine (Xeloda and generics) licensed for metastatic colorectal cancer, adjuvant colorectal settings and metastatic breast cancer as monotherapy or in combination.

NICE technology appraisals and local NHS trust formularies guide specific indications and regimen choices for capecitabine.

Off‑label and emerging uses seen in trials and practice include investigator‑led protocols for gastric and biliary cancers and metronomic low‑dose schedules for frail or elderly patients.

Capecitabine is increasingly used as a substitute for infusional 5‑FU to reduce hospital visits, with many trusts formalising community chemotherapy delivery.

In UK practice, off‑label use typically requires MDT discussion and clear documentation of clinical rationale.

DPD genotyping or phenotyping and renal function checks are standard pre‑treatment precautions before initiating capecitabine.

Dosage Strategy

What dosing patterns should patients and clinicians expect?

General dosing historically uses 1250 mg/m² twice daily for 14 days followed by seven days off, making a 21‑day cycle for many regimens.

Alternative starting ranges of 1000–1250 mg/m² twice daily are common depending on patient fitness and combination partners.

Renal impairment, age, body surface area and prior toxicity determine dose adjustments.

Avoid initiation if creatinine clearance is below 30 mL/min and reduce the starting dose by about 25–50% for CrCl 30–50 mL/min according to common protocols.

Condition‑specific examples: colorectal monotherapy often uses 1250 mg/m² twice daily on days 1–14 every 21 days.

When substituting for infusional 5‑FU in CAPOX, capecitabine may be given at 625 mg/m² twice daily continuously with oxaliplatin on day 1, per protocol.

In adjuvant breast settings post‑neoadjuvant therapy, trials have used extended or adjusted intermittent schedules tailored to tolerance and risk.

Practical UK tips: split tablets only if the product license and tablet formulation permit it, use a dosing diary to track adherence and ensure DPD testing is completed before starting.

Safety Protocols

Who must not take Xeloda and what are the main risks to watch?

Absolute contraindications are known hypersensitivity to capecitabine or 5‑FU, known DPD deficiency, severe renal impairment with CrCl under 30 mL/min, and pregnancy or breastfeeding.

Use caution in patients with significant cardiac disease, severe hepatic dysfunction, active infection, or pre‑existing severe neuropathy when combining with neurotoxic drugs.

Common adverse effects include hand‑foot syndrome, diarrhoea, nausea, mucositis, fatigue and myelosuppression.

Hand‑foot syndrome is the most frequent dose‑limiting toxicity and often requires early symptom education and dose modification.

Rare but serious risks include cardiotoxicity (angina, myocardial infarction or arrhythmias) and severe diarrhoea with dehydration.

UK practice mandates baseline blood counts and renal function checks, patient education about red flags, and prompt dose reduction or interruption for grade 2 or worse toxicities.

Provide patients with written emergency instructions and clear oncology contacts for severe symptoms such as chest pain, breathlessness or uncontrolled diarrhoea.

Interaction Mapping

Can I take Xeloda with food or my usual medicines?

Food has minimal effect on capecitabine absorption but taking tablets with water within 30 minutes after a meal is advised to reduce gastrointestinal irritation and improve tolerability.

Clinically important drug interactions include warfarin, where capecitabine can increase INR and bleeding risk; intense monitoring of INR is required if both drugs are given.

Sorivudine and brivudine are strictly contraindicated due to fatal potentiation of 5‑FU; these antivirals must never be co‑prescribed with capecitabine.

Avoid live vaccines in immunocompromised patients receiving chemotherapy.

Combining capecitabine with other agents requires attention to overlapping toxicities, for example increased neurotoxicity when used with oxaliplatin and potential cardiac monitoring when combined with trastuzumab.

Pharmacist medication reconciliation is important in older patients to review anticoagulation strategies and other co‑medications.

Patient Experience Analysis

Do patients prefer tablets to infusions and what problems do they report?

UK surveys from 2023–2025 show patients value the convenience of oral capecitabine and the reduced hospital time compared with IV 5‑FU.

Adherence in trial settings is typically over 80% when structured follow‑up is in place, but real‑world adherence declines when support is minimal.

Top patient concerns are the impact of hand‑foot syndrome on daily tasks, diarrhoea causing dehydration and anxiety about managing oral cytotoxics at home.

Forum trends emphasise practical self‑care: cooling packs, regular emollient use for HFS, dietary tweaks for diarrhoea and pill organisers for dose tracking.

Patients praise remote toxicity monitoring but often request clearer written instructions and faster access to oncology teams for urgent problems.

Clinician interventions that improve outcomes include nurse‑led phone clinics, pre‑treatment education sessions and plain explanations of DPD testing.

Distribution And Pricing Landscape

How is Xeloda supplied across the NHS and what affects price?

Xeloda (Roche) and multiple generics are dispensed via NHS hospitals and hospital‑at‑home or community chemotherapy programmes on prescription.

Tendering by NHS trusts and competition from generics drive down the cost per tablet and per cycle in most procurement models.

Supply resilience since 2022 has improved through parallel sourcing, though occasional active‑substance shortages can force local switches between brands.

Capecitabine requires ambient storage and does not need cold chain handling; store between 15–30°C in original blister packs until use.

NHS covers approved indications and private prescriptions follow market pricing rules.

In our online pharmacy, xeloda is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Pharmacists should confirm batch and expiry on receipt and report shortages promptly to Trust pharmacy leads.

Alternative Options

What are the alternatives to capecitabine and when might they be chosen?

Capecitabine versus infusional 5‑FU/leucovorin: capecitabine offers home administration and avoids pumps and central lines, but has higher likelihood of hand‑foot syndrome.

Infusional 5‑FU avoids HFS in many patients but requires ambulatory pumps or inpatient infusions and carries different risks such as catheter complications.

Other systemic options depend on tumour type and include S‑1 where available, irinotecan or oxaliplatin‑based regimens, and combinations with targeted agents or immunotherapies guided by local protocols.

Advantages of capecitabine are oral convenience, an established evidence base in colorectal and breast cancer, and standardised dosing algorithms.

Disadvantages include dependence on patient adherence, the very high toxicity risk with unrecognised DPD deficiency and renal limitations.

MDT decisions in UK centres weigh clinical factors, patient preference and community nursing availability when choosing between oral and IV options.

Regulatory Status

What rules and safety systems govern Xeloda in the UK?

Capecitabine is MHRA‑licensed in the UK for its authorised indications and appears in NICE appraisals for cost‑effective use in certain settings.

DPD testing has become standard practice in many UK centres following regulatory safety alerts to reduce risk of severe toxicity.

Xeloda packaging and labelling follow UK and EU prescription cytotoxic requirements and the product is subject to pharmacovigilance reporting.

Clinicians and pharmacists are expected to file Yellow Card reports for suspected adverse drug reactions, including rare cardiotoxic events.

Local Trust formularies govern procurement and off‑label use governance for capecitabine across NHS services.

Consolidated FAQ

What are the practical questions patients and clinicians ask most often?

How is Xeloda taken?

Take the tablets twice daily within 30 minutes after food, following the prescribed schedule—commonly 14 days on then seven days off.

What safety checks are needed?

Baseline renal and blood counts, DPD testing and cardiac history review where indicated are standard before starting capecitabine.

What are emergency signs?

Severe diarrhoea or vomiting, breathlessness, chest pain or acute confusion require urgent care via NHS 111 or emergency services and immediate oncology contact.

Can it be used at home?

Yes; many community chemotherapy services support home use with local monitoring and remote nurse follow‑up.

What interactions matter most?

Monitor INR closely if a patient is on warfarin and avoid contraindicated antivirals such as sorivudine.

Is it safe in pregnancy?

No; capecitabine is contraindicated in pregnancy and effective contraception is required for patients of childbearing potential.

How are dose adjustments handled?

Dose reduction or interruption is used for grade 2 or worse toxicities and lower starting doses are advised for renal impairment.

Visual Guide

What should appear on patient handouts and clinic posters?

Include a clear pictogram of the dosing schedule showing morning and evening tablets and the 14‑on, seven‑off cycle where applicable.

Use red‑flag icons for severe diarrhoea, chest pain, breathlessness and severe hand‑foot syndrome, and list oncology nurse contact details prominently.

Provide a simple explanation of DPD and renal checks, and practical HFS tips such as moisturisers, avoiding hot water and reducing friction on hands and feet.

Clinic visuals should include a pre‑treatment flowchart (DPD, renal, bloods), an algorithm for dose modifications by toxicity grade and a comparison table of capecitabine versus IV 5‑FU side‑effect frequencies.

Offer downloadable PDFs in large font and plain English to meet NHS Accessible Information Standard requirements.

Storage And Transport

How should capecitabine be stored, transported and disposed of?

Store capecitabine tablets at controlled room temperature, generally 15–30°C, keeping them in their original blister pack until use.

Transport under normal pharmaceutical shipping conditions; no specialised cold chain is required.

Disposal follows cytotoxic waste policies—unused tablets should be returned to the hospital pharmacy or disposed of per local hazardous‑waste protocols.

Community nurses delivering tablets should use tamper‑evident packaging and pharmacists must check batch and expiry on receipt and maintain stock rotation.

Guidelines For Proper Use

What checklist should clinicians follow and what practical tips help patients stick to treatment?

Clinician checklist: confirm the approved indication, perform DPD testing and baseline renal and haematologic evaluation, document counselling on risks and contraception, give a written dosing schedule and oncology contact numbers, and schedule early toxicity review at two weeks.

For combination therapy, verify partner drug dose adjustments and baseline checks such as cardiac assessment or neuropathy screening.

Patient adherence tips: use a dosing diary or phone alarm, align doses with meals, keep a small card with dose times and emergency numbers and report early signs of HFS or diarrhoea promptly.

Consider lower starting doses and close community nursing support for elderly or frail patients, and remind patients about Yellow Card reporting for suspected adverse reactions.

Delivery Across United Kingdom